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Abstract
Background: Influenza is major public health threat worldwide, yet the diagnostic accuracy of rapid tests in developing
country settings is not well described.
Methodology/Principal Findings: To investigate the diagnostic accuracy of the QuickVue Influenza A+B test in a primary
care setting in a developing country, we performed a prospective study of diagnostic accuracy of the QuickVue Influenza
A+B test in comparison to reverse transcriptase-polymerase chain reaction (RT-PCR) in a primary healthcare setting in
children aged 2 to 12 years in Managua, Nicaragua. The sensitivity and specificity of the QuickVue test compared to RT-PCR
were 68.5% (95% CI 63.4, 73.3) and 98.1% (95% CI 96.9, 98.9), respectively, for children with a fever or history of a fever and
cough and/or sore throat. Test performance was found to be lower on the first day that symptoms developed in comparison
to test performance on days two or three of illness.
Conclusions/Significance: Our study found that the QuickVue Influenza A+B test performed as well in a developing country
primary healthcare facility setting as in developed country settings.
Citation: Gordon A, Videa E, Saborio S, Lo ´pez R, Kuan G, et al. (2009) Performance of an Influenza Rapid Test in Children in a Primary Healthcare Setting in
Nicaragua. PLoS ONE 4(11): e7907. doi:10.1371/journal.pone.0007907
Editor: Robyn Klein, Washington University School of Medicine, United States of America
Received August 31, 2009; Accepted October 21, 2009; Published November 19, 2009
Copyright:  2009 Gordon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the Pediatric Dengue Cohort Initiative, J. Craig Venter Institute, and the United States Centers for Disease Control and
Prevention. Rapid tests were kindly provided by Quidel Corporation. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: None of the authors has any relationships or support that might be perceived as constituting a competing interest, except that Quidel
Corporation covered the costs of airfare and hotel for AG at one conference in February 2009.
* E-mail: eharris@berkeley.edu
Introduction
Influenza is a major health threat throughout the world [1], yet
many countries lack even rudimentary influenza surveillance
systems [2,3]. Furthermore, influenza surveillance in developing
countries often includes only major cities due to limited laboratory
resources in outlying areas and poor infrastructure, such as lack of
electrical power. Consequently, data are lacking about the types of
influenza viruses that are circulating and the burden of influenza-
related disease in the developing world.
Logistical constraints in developing countries largely dictate the
types of laboratory tests available for use in influenza surveillance.
While reverse transcriptase-polymerase chain reaction (RT-PCR)
and viral isolation are the preferred diagnostic methods, rapid
influenza tests are valuable for their ease of use and laboratory-
independence. In the developed world, rapid influenza tests have
been evaluated in both laboratory and clinical settings, yielding
sensitivities of 45–90% and specificities of 86–100% [4,5,6,7,8,9,10]
in comparison to viral isolation and RT-PCR. In developing
countries, the performance characteristics of rapid influenza tests
are not well documented in primary health care settings, where
infrastructure is unreliable, conditions are often hot and humid, and
staff may have littleor noexperience with the collection of respiratory
samples, yet where rapid tests may aid in influenza surveillance.
Historically, viral isolation has been regarded as the ‘‘gold standard’’
for diagnosis of influenza infection. However, recently a number of
studies have demonstrated the superior sensitivity of RT-PCR for the
detection of influenza viruses [11,12,13,14], and influenza experts have
recommended that RT-PCR be regarded as the new diagnostic
standard [14,15]. Surveillance systems in developed countries and
some developing countries have switched to using RT-PCR as the
primary laboratory diagnostic test, with viral isolation performed
primarily on RT-PCR-positive specimens. For this reason, the
QuickVue rapid test was compared to RT-PCR in this study.
To examine the diagnostic accuracy of the QuickVue Influenza
A+B test in comparison to RT-PCR in children treated in a primary
healthcare facility in a developing country, we performed a
prospective study in Managua, Nicaragua and report the results here.
Methods
Ethics Statement
This study was approved by the institutional review boards at
the University of California (UC) Berkeley and the Nicaraguan
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the parents or guardians of all participants.
Study Population and Site
This study was performed as part of the Nicaraguan Influenza
Cohort Study (NICS), a prospective community-based cohort
study of approximately 3,800 children 2–14 years old in Managua,
Nicaragua [16]. Healthy children aged 2–12 years residing in the
study area were enrolled beginning in June 2007. Children were
eligible to remain in the study through the age of 14 or until they
moved from the study area. To maintain the age structure of the
cohort, new two-year-olds were recruited in July-September of
each year. The primary study site was the Health Center Socrates
Flores Vivas (HCSFV), a public primary health care facility in the
capital of Nicaragua. Respiratory specimens were collected and
the rapid test was performed in the HCSFV’s clinical laboratory.
A number of measures were taken to encourage participants to
attend the HCSFV at the first sign of illness. These measures
included: 1) at enrollment, parents agreed to bring their child to
the health center at the first sign of illness; 2) participants were
provided with free healthcare 24 hours a day, 365 days a year; 3)
participants were provided with rapid diagnostic testing free of
charge; and 4) a study ambulance was available at all times at the
heath center. Children who required hospitalization or tertiary-
level care were transferred to a hospital by study staff. In yearly
participation surveys, 1.7% to 2.5% of participants reported
attending a healthcare provider outside of the study.
Procedures
All specimens collected between January 1, 2008 and December
31, 2008 from children in the NICS who presented with a fever, or
history of fever or feverishness, and cough and/or sore throat
within five days of symptom onset were included in the study.
Information from all medical appointments was systematically
collected using standardized data collection forms. Data included
age, sex, two measurements of temperature, date of fever onset,
and other symptoms. Upon presentation with testing criteria,
children were randomly selected for respiratory testing using a
random number generator and then referred to the HCSFV
clinical laboratory. There, a nasal swab was first collected for the
rapid test, QuickVue Influenza A+B, using the swab provided in
the kit. Then nasal and throat Dacron swabs were collected and
placed into one tube containing three mL of viral transport
medium for RT-PCR and viral culture. The QuickVue test was
performed onsite immediately. Samples for RT-PCR and viral
isolation collected on workdays (Monday–Saturday) were kept at
4uC and processed within 16 hours. Samples collected on Sundays
and holidays were stored for up to 48 hours prior to processing.
QuickVue Influenza A+B is a lateral-flow immunoassay that
detects and differentiates between influenza A and B. Tests were
performed according to the manufacturer’s instructions. Tests
were read after exactly ten minutes and were considered negative
if, at ten minutes, a pink line had not appeared to indicate a
positive influenza A or B result. Tests were considered invalid if
the blue control line did not appear or if the background color
made it impossible to read the test result. Invalid tests were
repeated once.
Laboratory Methods
Samples were transported to the National Virology Laboratory
at the Nicaraguan Ministry of Health, where RNA was extracted
from nasal swabs using the QIAampH Viral RNA Mini Kit.
(Qiagen Sciences, Germantown, MD) Influenza viruses A and B
were amplified using Promega Access RT-PCR (Promega
Corporation, Madison, WI) and typed in-house according to a
protocol provided by the Centers for Disease Control and
Prevention (CDC). Laboratory technicians were trained in how
to perform RT-PCR, including attendance at influenza testing
workshops held by the CDC and World Health Organization and
hands-on training by study personnel from UC Berkeley.
Laboratory technicians performing RT-PCR testing were blinded
to the results of the rapid test and to the patients’ clinical
presentation.
Rapid Test Training
To replicate the typical training resources that would be
available if rapid tests were widely distributed in a developing
country setting, a 1.5-hour training session was held. This training
consisted of a short presentation explaining the symptoms and
burden of influenza, influenza surveillance, collection of nasal
swabs, principles of the QuickVue rapid test, and instructions on
how to perform the test. Laboratory technicians then practiced
taking one nasal swab specimen and performing a rapid test. Prior
to the training session, technicians had never performed an
influenza rapid test and many had little or no experience collecting
nasal swab specimens.
Statistical Analyses
The main outcomes of this study were the sensitivity, specificity,
positive predictive value (PPV), and negative predictive value
(NPV) of the QuickVue Influenza A+B test compared with RT-
PCR. Agreement between tests was calculated using the kappa
statistic. Sub-analyses were performed to examine test perfor-
mance stratified by testing criteria, day of presentation, age, and
sex. All statistical analyses were performed using STATA 10.1
(StataCorp, College Station, Texas).
Results
Between January 1, 2008, and December 31, 2008, 3,916
children participated in the cohort study. During this period, study
participants attended 13,666 medical visits, of which 3,935 (29%)
met the testing criteria. Of these, 1,195 (30%) were randomly
selected for influenza testing, and 1,157 duplicate specimens (97%)
were collected from 989 children and tested by both rapid test and
RT-PCR, while 38 children received a rapid test only (Figure 1).
Demographic data for the children that contributed samples are
presented in Table 1. In total, 359 samples (31%) tested positive
for influenza by RT-PCR, with 224 (19%) testing positive for
influenza A and 135 (12%) for influenza B. Of the 74 influenza
A-positive samples that underwent subtyping by RT-PCR, 73
were positive for seasonal influenza A H1N1 and one for influenza
A H3N2. The QuickVue test detected virus in 246 influenza RT-
PCR-positive samples, including 146 influenza A-positive samples
and 100 influenza B-positive samples. One invalid QuickVue test
result was repeated and found to be negative for influenza.
Data on the agreement of RT-PCR and rapid test are presented
in Table 2. Overall, the sensitivity and specificity of the QuickVue
test compared to RT-PCR for influenza A or B were 68.5% (95%
CI 63.4, 73.3) and 98.1% (95% CI 96.9, 98.9), respectively. The
corresponding PPV was 93.9% (95% CI 90.3, 96.5), and the NPV
was 88.1% (95% CI 85.9, 90.1) (Table 3). The sensitivity and
specificity of the test in children under six and in those aged six
and over were similar (data not shown).
Limiting the analysis to the 578 samples from patients who met
the CDC definition of influenza-like illness, defined as a fever of
$37.8uC plus cough or sore throat, resulted in a slightly higher
sensitivity for the rapid test but did not significantly change the
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sensitivity of the rapid test was 72.1% (95% CI 66.3, 77.5) and the
specificity was 98.1% (95% CI 95.9, 99.3). Performance of the
rapid test by day of presentation was examined both for the entire
study population and for the subgroup meeting the definition of
ILI. In both analyses, the rapid test had a lower sensitivity on the
day of symptom onset and on the fourth day of illness when
compared to the sensitivity on day two or three of illness (Table 4).
Discussion
Our study found that the QuickVue Influenza A+B test
performed with a moderate sensitivity (68.5%) and high specificity
(98.1%) in comparison to RT-PCR in a developing country
primary care setting. Laboratory technicians found the test easy to
use and needed minimal training to adequately perform the test.
In the US and other developed countries, the QuickVue
Influenza A+B rapid test has been found to have a sensitivity of
67%–85% and specificity of 97%–100% [8,17]. However, one
recent study conducted in three sites in the US found the test
performed with a significantly lower sensitivity (19%–32%)[18].
One study performed in a developing country reported the
QuickVue test to have a sensitivity and specificity of 71% and
98%, respectively, in patients aged one month to 85 years in
hospital outpatient clinics in Thailand [15]. As most of these prior
studies included only patients meeting the CDC/WHO definition
of ILI, it is more appropriate to compare the results of our sub-
analysis limited to children with ILI to these studies. Thus, the
sensitivity of 72.1% (95% CI 66.3, 77.5) and specificity of 98.1%
(95% CI 95.9, 99.3) we observed are well within the ranges of the
sensitivities and specificities previously reported.
Importantly, a substantial number of participants (23%)
presented on the first day of illness, and the sensitivity of the
rapid test was found to be lower among children who presented
and were tested on the first day. Few studies of rapid tests have
captured data on these early cases. In a study in Hong Kong,
researchers examined the performance of the QuickVue rapid
test and did not find a significant difference in the first 24 hours
following symptom onset [19]. One possible explanation for our
differing results is that the Hong Kong study population was
very different from ours. Subjects were predominantly adults
a n dw e r er e c r u i t e db e c a u s et h e yw e r es e e k i n gm e d i c a lc a r ea ta n
outpatient clinic, and therefore might have been sicker and
hence have a higher viral load than our study subjects at the
time of testing. In a recent meta-analysis of influenza volunteer
c h a l l e n g es t u d i e s ,s y m p t o m sw e r er e p o r t e di nt h ef i r s t2 4h o u r s
following virus inoculation, a dayb e f o r ep e a kv i r a ll o a da n dt w o
days before the peak of symptoms [20]. It is possible that early
in illness, children are symptomatic at relatively low viral loads,
leading to the lower sensitivity we report on day 1. More studies
are needed to elucidate the natural history of influenza infection
in children.
Figure 1. Flowchart of sample selection, Managua, Nicaragua,
2008. Flowchart diagramming the selection of samples used to analyze
the performance of the QuickVue Influenza A+B rapid test. Due to
complications related to transport and sample separation, samples
(n=37) collected during holiday periods lasting longer than 3 days did
not undergo RT-PCR and therefore were not included in this study.
doi:10.1371/journal.pone.0007907.g001
Table 1. Demographic description of study participants,
Managua, Nicaragua, 2008.
All cases
n=1,157
Cases with influenza-like illness
n=578
Sex
Female 581 (50.2) 301 (52.1)
Age (years)
2 84 (7.3) 42 (7.3)
3 169 (14.6) 92 (15.9)
4 166 (14.4) 79 (13.7)
5 158 (13.7) 76 (13.2)
6 129 (11.2) 75 (13.0)
7 113 (9.8) 63 (10.9)
8 113 (9.8) 52 (9.0)
9 79 (6.8) 34 (5.9)
10 53 (4.6) 23 (4.0)
11 53 (4.6) 26 (4.5)
12 36 (3.1) 15 (2.6)
13 4 (0.4) 1 (0.2)
doi:10.1371/journal.pone.0007907.t001
Table 2. Agreement between the QuickVue Influenza A+B
test and RT-PCR, Managua, Nicaragua, 2008.
Patients with fever or a history of fever and cough and/or sore throat (n=1,157)
RT-PCR Agreement (%) Kappa (95% CI)
+ 2
QuickVue + 246 15 88.9 0.72 (0.67, 0.76)
2 113 783
Patients with a temperature $37.8uC and cough and/or sore throat (n=578)
RT-PCR Agreement (%) Kappa (95% CI)
+ 2
QuickVue + 189 6 86.3 0.72 (0.65, 0.77)
2 73 310
doi:10.1371/journal.pone.0007907.t002
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the cohort study protocol, in which families of participants were
asked to bring in their children at the first sign of illness. However,
persons with influenza typically do not present until several days
into the illness. Therefore, it is likely that the sensitivity and
resulting positive predictive values we observed are underestimates
of the test’s performance in the clinical setting, since it is less
common for patients to present on the day of symptom onset.
However, during an influenza pandemic, patients may present
very early following symptom onset; thus, it is imperative to
evaluate the performance of any rapid test in detecting influenza
very early after onset of illness.
One of the limitations of this study is the age range of the
patients. Because the study was restricted to children aged 2–14
years, the sensitivities and specificities we found apply only to this
group. However, because the rapid test performed at approxi-
mately the same level in this study as in studies performed in
children in developed country settings, the rapid test may well
perform at the same level across all age ranges in developing
country settings as observed in studies conducted in developed
countries. Another limitation of this study is the use of RT-PCR as
the gold standard. However, considering the very high (,98%)
specificity of the rapid test in this study and the fact that RT-PCR
is substantially more sensitive than viral isolation, it is unlikely that
use of RT-PCR alone, instead of a combination of RT-PCR and
viral isolation, significantly affected the results.
In conclusion, the rapid influenza test we used performed well in
a primary healthcare setting in Managua, Nicaragua. Clinical
laboratory staff needed minimal training to correctly perform the
test and found the test easy to perform. Further evaluation of rapid
tests in developing countries is needed to determine the feasibility
of using these tests to augment existing surveillance systems and for
quick deployment in the event of an influenza pandemic, as well as
for use in clinical decision-making.
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Table 3. Performance of the QuickVue Influenza A+B Test, Managua, Nicaragua, 2008.
Number Positive Sensitivity Specificity Positive Predictive Value Negative Predictive Value
(%) (95% CI) (%) (95% CI) (%) (95% CI) (%) (95% CI)
Children presenting with a fever or reported fever and cough and/or sore throat (n=1,157)
Influenza 359 68.5 (63.4, 73.3) 98.1 (96.9, 98.9) 94.3 (90.7, 96.7) 87.4 (85.0, 89.5)
Influenza A 224 65.2 (58.5, 71.4) 99.1 (98.3, 99.6) 94.8 (90.0, 97.7) 92.2 (90.4, 93.8)
Influenza B 135 74.1 (65.8, 81.2) 99.1 (98.3, 99.6) 91.7 (84.9, 96.2) 96.7 (95.4, 97.7)
Children presenting with a fever $37.8uC and cough and/or sore throat (n=578)
Influenza 262 72.1 (66.3, 77.5) 98.1 (95.9, 99.3) 96.9 (93.4, 98.9) 80.9 (76.6, 84.8)
Influenza A 169 69.8 (62.3, 76.6) 99.3 (97.9, 99.8) 97.5 (92.9, 99.5) 88.8 (85.6, 91.6)
Influenza B 93 76.3 (66.4, 84.5) 99.2 (97.9, 99.8) 94.7 (86.9, 98.5) 95.6 (93.5, 97.2)
doi:10.1371/journal.pone.0007907.t003
Table 4. Performance of the QuickVue Influenza A+B Test in children by day post-onset of symptoms, Managua, Nicaragua, 2008.
Sample Number Number Positive Sensitivity Specificity Positive Predictive Value Negative Predictive Value
(%) (95% CI) (%) (95% CI) (%) (95% CI) (%) (95% CI)
Patients with fever or a history of fever and cough and/or sore throat (n=1,157)
Day 1 263 79 51.9 (40.4, 63.3) 98.4 (95.3, 99.7) 93.2 (81.3, 98.6) 82.6 (77.0, 87.4)
Day 2 578 189 75.1 (68.3, 81.1) 97.9 (96.0, 99.1) 94.7 (89.8, 97.7) 89 (85.7, 91.8)
Day 3 211 66 74.2 (62.0, 84.2) 97.9 (94.1, 99.6) 94.2 (84.1, 98.8) 89.3 (83.4, 93.6)
Day 4 90 19 57.9 (33.5, 79.7) 98.6 (92.4, 100) 91.7 (61.5, 99.8) 89.7 (80.8, 95.5)
Patients with a fever $37.8uC and cough and/or sore throat (n=578)
Day 1 182 62 59.7 (46.4, 71.9) 97.5 (92.9, 99.5) 92.5 (79.6, 98.4) 82.4 (75.1, 88.3)
Day 2 284 147 76.9 (69.2, 83.4) 98.5 (94.8, 99.8) 98.3 (93.9, 99.8) 79.9 (73.0, 85.6)
Day 3 78 39 79.5 (63.5, 90.7) 97.4 (86.5, 99.9) 96.9 (83.8, 99.9) 82.6 (68.6, 92.2)
Day 4 26 11 54.5 (23.4, 83.3) 100 (78.2, 100) 100 (54.1, 100) 75.0 (50.9, 91.3)
Note: Day 1 refers to the day of symptom onset.
doi:10.1371/journal.pone.0007907.t004
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